Answers are grounded in this paper and cite their sources.
Pharmaceutical supply chains are increasingly exposed to disruptions arising from concentrated manufacturing, limited sources of active pharmaceutical ingredients and critical materials, quality failures, transportation constraints, demand volatility, geopolitical instability, and regulatory dependencies. These vulnerabilities are particularly consequential because interruptions in pharmaceutical supply can affect medication availability and continuity of patient care. This study develops a strategic management framework for pharmaceutical supply resilience centered on the ability to protect medication availability under uncertain operating conditions. The framework integrates six capabilities: Anticipate, Diversify, Buffer, Detect, Coordinate, and Recover . Anticipation identifies critical dependencies before disruption occurs; diversification reduces exposure to common points of failure; buffering provides targeted protection for medicines whose recovery or substitution may require time; detection creates an early-warning capability based on supply, inventory, and demand signals; coordination connects manufacturers, distributors, procurement teams, pharmacists, clinicians, quality functions, and regulatory actors; and recovery links restoration of supply with organizational learning. The framework emphasizes differentiated resilience strategies based on medication criticality, supply concentration, substitutability, lead time, and recovery capability instead of uniform increases in inventory or supplier numbers. Pharmacy operations are incorporated as a key interface between upstream supply conditions and clinical demand, providing evidence of emerging shortages and their operational consequences. The study further examines how strategic sourcing, risk-adjusted inventory, digital visibility, quality management, and regulatory coordination can strengthen continuity while preserving pharmaceutical standards and economic sustainability. By connecting preparedness, response, and recovery within a single management architecture, the framework provides a practical basis for strengthening pharmaceutical supply continuity in environments characterized by increasingly interconnected disruptions.
No takes yet. Share an insight, caveat, or question.
Maysa Meredova (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: